Aytu Biopharma, Inc.
AYTU
$2.39
$0.0954.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.57% | -13.48% | -6.98% | -41.51% | -38.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.57% | -13.48% | -6.98% | -41.51% | -38.31% |
| Cost of Revenue | 54.09% | 31.12% | -3.98% | -56.11% | -63.32% |
| Gross Profit | 23.60% | -26.14% | -8.08% | -31.93% | -18.69% |
| SG&A Expenses | -8.64% | -2.96% | -12.93% | -21.33% | -49.04% |
| Depreciation & Amortization | 0.00% | 0.33% | -0.32% | 9.04% | -23.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.25% | 6.39% | -10.51% | -32.76% | -51.98% |
| Operating Income | 278.94% | -112.02% | 83.16% | -128.44% | 85.44% |
| Income Before Tax | 316.07% | -72.69% | 120.05% | -59.63% | 75.46% |
| Income Tax Expenses | -123.42% | -136.28% | -- | -- | -- |
| Earnings from Continuing Operations | 272.20% | 7.43% | 114.63% | -87.91% | 68.22% |
| Earnings from Discontinued Operations | 109.02% | 114.66% | 158.89% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 238.34% | 458.18% | 118.15% | -87.91% | 59.90% |
| EBIT | 278.94% | -112.02% | 83.16% | -128.44% | 85.44% |
| EBITDA | 1,976.67% | -80.53% | 31.25% | -76.75% | 102.54% |
| EPS Basic | 224.80% | 422.06% | 116.40% | -38.57% | 73.00% |
| Normalized Basic EPS | 326.16% | 9.27% | 127.58% | -90.58% | 87.07% |
| EPS Diluted | 139.60% | -523.75% | 89.33% | -38.57% | 73.00% |
| Normalized Diluted EPS | 269.07% | -21.07% | 118.39% | -90.58% | 87.07% |
| Average Basic Shares Outstanding | 10.86% | 11.14% | 10.69% | 35.61% | 48.48% |
| Average Diluted Shares Outstanding | 48.27% | 53.78% | 65.99% | 35.61% | 48.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |